ETFs Astellas Pharma Inc. OTC Markets

ALPMY

US04623U1025

Pharmaceuticals

Delayed OTC Markets 21:25:18 21/10/2026 +03			5-day change	1st Jan Change
15.68 ^USD	+1.29%		+9.27%	+17.98%

10-08	Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer	MT
10-08	Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer	CI

ETFs positioned on Astellas Pharma Inc.

Name	YTD change	Weight	AuM
SGI ENHANCED GLOBAL INCOME ETF - USD	+15.14%	0.18%	105 M€
ISHARES DYNAMIC EQUITY ACTIVE ETF - USD	+8.59%	0.04%	3,163 M€
ACTIVEPASSIVE INTERNATIONAL EQUITY ETF - USD	+8.70%	0.03%	1,166 M€

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Employees

14,099

Sector

Pharmaceuticals

Calendar

11-04 Earnings release - Q2 2027

More about the company